Synthesis-to-Clinic

This unique platform allows ¹⁴C clinical studies to be delivered as a fully integrated service.  This not only increases the efficiency with which these programmes can be executed but also dramatically simplifies the procurement process, delivering significant financial and timeline savings.

Synthesis-to-Clinic^TM is built on our “best in class” technologies and capabilities, including:

Chemistry – 10,000 custom syntheses completed to date by staff with more than 1000 years combined experience give Quotient unrivalled experience in ¹⁴C radiolabelling.  We are directly responsible for 1/3 of the molecules in the industry’s development pipeline or on the market.

Preclinical – we provide a comprehensive service encompassing the full range of regulatory drug metabolism studies.  Hundreds of molecules have passed through our hands and our premium quality data have supported a number of internationally marketed products.

Clinical – We have completed over 100 human ADME studies to date in healthy volunteers or oncology patients.  We have investigated more than 50 compounds using microdosing and microtracer techniques via different routes of administration.

We can manage and implement the entire supply chain for any ¹⁴C Synthesis to Clinic programme.  The complete project is coordinated through a single project manager, removing the usual extensive vendor management burden from our clients.  Operational plans are tightly integrated ensuring that projects are delivered in the shortest possible timeframe.

For more information download the Synthesis-to-Clinic Fact sheet.